Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Romidepsin in R/R Mature T-cell Lymphoma
NCT04233697Phase 1Withdrawn
- Sponsor
- Columbia University
- Start
- Feb 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of copanlisib in mature T-cell lymphoma (PTCL), sponsored by Columbia University. Primary endpoints: Maximum Tolerated Dose at 2 years, Recommended Phase 2 Dose and 1 more. Planned start Feb 2020; status: withdrawn.
02
Drugs
copanlisib
03
Conditions
mature T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04233697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233697.